--(BUSINESS WIRE)--Regenetech believes its technology solves the major barrier to wide-spread and general clinical use of Adult Stem Cells for a large variety of proven therapies. Over its five years of operation, Regenetech has extended NASA-invented technology to allow Adult Stem Cells separated from peripheral blood or umbilical cord blood samples to be “expanded” (i.e., the population of cells grown) to therapeutic dose level in six to seven days. This is done with the Intrifuge™ Bioreactor equipped with the NASA-patented Time-Varying Electromagnetic Field (TVEMF) system.
